TheStreet.com RealMoney.com IPOPros.com TheStreetPros.com Your Money/Shopping Help
Home 

Latest Stories 

My Portfolio 

Message Boards 

Cramer's Trading Diary 

Columnist Conversation 

TSC Conferences 

Analyst Rankings 

TheStreet.com 
Home 

Market Briefing 

Market News 

Stock News 

Tech Stocks 

Personal Finance 

Commentary 

International 

Tools/Quotes 

Special Reports 

Investing Basics 

Chats & Appearances 

TSC Audio/Video 

TSC Wireless 

Sports Scores 

Letters 

Corrections 


Commentary: Wrong! Tactics and Strategies

Bricks in the Wall: Part 3
By James J. Cramer

8/1/00 10:33 AM ET


Editor's note: This article is the final installment of a 3-part series. Please be sure to check out Part 1 and Part 2, which were published earlier this morning!


Continuation of the "What Went Wrong?" checklist:

7. Merger and acquisition activity peaked with the dinging of the Sprint (PCS:NYSE - news - boards) deal. This collapse, coupled with the earnings disappointment for WorldCom (WCOM:Nasdaq - news - boards), meant an end to the mass consolidation in the sector. Smaller players can still get bids, but the larger players won't get gobbled so fast. I think this will get better in the fall if Bush wins, because I can imagine that guy dismantling antitrust.

8. Short-term rate-rise expectations crushed the financials. This group had been humming, with many of its players hitting 52-week highs. Wachovia's (WB:NYSE - news - boards) nasty blowup took care of the 52-week high fever, and possible rate increases kiboshed anything else that could happen positively. I think the negatives here are well-discounted, but I am not running out to buy the group.

9. Pfizer (PFE:NYSE - news - boards), which had become the leader of a resurgent drug group, blew the quarter. This was a terrible blow to drug investors who had begun to think that Pfizer had regained the luster it had a couple of years ago. Merger savings don't seem to stanch the bleeding here. Lilly (LLY:NYSE - news - boards) can't do what Pfizer could.

10. Philip Morris (MO:NYSE - news - boards) lost the big case that had been holding it back. A win in this class-action case in Florida would have kept the food group, another leader, cooking well into the fall. Instead, the biggest-cap in the business lost its footing. I think this stock comes back, but it doesn't have any momentum.

There's your checklist. Lots of stuff went wrong. Some of it can be undone, most can't. Which is why we aren't going anywhere anytime soon. We will bounce around with 3% gains and 4% drops, mixed with 4% gains and 3% drops as we get closer to NDX 3300. Boring, range-bound, frustrating. Get used to it. It will be like that for some time.


Hurry! Time is running out to see James J. Cramer live in New York City on August 7, 2000. Click here for details: http://www.bigfishinc.com/cramerlive


James J. Cramer is manager of a hedge fund and co-founder of TheStreet.com. At time of publication, his fund was long Philip Morris. His fund often buys and sells securities that are the subject of his columns, both before and after the columns are published, and the positions that his fund takes may change at any time. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. Cramer's writings provide insights into the dynamics of money management and are not a solicitation for transactions. While he cannot provide investment advice or recommendations, he invites you to comment on his column at jjcletters@thestreet.com.
Send letters to the editor to letters@realmoney.com.
Read our conflicts and disclosure policy.
Order reprints of RealMoney.com articles. Top




Sponsored Links







Home | Top



© 2000 The Street.com inc, All Rights Reserved.

TOOLS/QUOTES
Enter symbol or name:
Real-Time Quote
News
Research
My Portfolio